Skip to main content
OpenTrials
Completed

NCT Number: NCT05067881

Post-COVID-19 Pneumo-hematocele

Introduction. As the COVID-19 pandemic has continued, an increasing number of long-term complications are emerging. Recently, the appearance of characteristic pulmonary lesions has been noted, being described as post COVID-19 pneumatocele. The aim of this study is to describe the clinical, histopathologic and imaging features of post COVID-19 pneumo-hematoceles (PHC) and secondarily to suggest a treatment algorithm in these patients.

Methods. A retrospective study was performed in patients admitted with diagnosis of SARS-CoV2 infection from March 2020 to September 2021 who presented PHC on imaging studies. Clinical and demographic variables were recorded and CT scans were analyzed. A logistic regression analysis was performed to determine the risk for rupture according to PHC characteristics.

It appears that PHC occurs secondary to encapsulation of blood accumulation, the result of micro capillary bleeding, with partial reabsorption of blood and subsequent air filling. The recommendation is to operate on patients with PHC of 5cm and those with persistent lesions of 3cm.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Respiratory Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Karla Verónica Chávez Tostado

Mexico City, 14500, Mexico

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults with a positive protein chain reaction for SARS-CoV2,
  • PHC on imaging studies.

Exclusion criteria

  • loss of follow up
  • age out of range.

Treatment and study plan

Pulmonary resection

Procedure

Resection of pneumohematocele

Primary outcomes

  1. PHC diagnosis

    Time frame: From date of diagnosis until 4 weeks after diagnosis

    Pneumohematoceles on imaging studies

Sponsors and collaborators

Lead sponsor

Hospital General Ajusco Medio

Other

Collaborators

  • Instituto Nacional de Enfermedades Respiratorias

Registry information

Official study title

Post COVID-19 Pneumo-hematocele: Clinical Presentation and Treatment Pathway

Acronym: PHC

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Oct 5, 2021
Registry last updated
Oct 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.